Heparanase, heparin and the coagulation system in cancer progression

Thrombosis Research

Volumn 120, Issue SUPPL. 2, 2007, Pages

  Vlodavsky, Israel ^a   Ilan, Neta ^a   Nadir, Yona ^a,b   Brenner, Benjamin ^b   Katz, Ben Zion ^c   Naggi, Annamaria ^d   Torri, Giangiacomo ^d   Casu, Benito ^d   Sasisekharan, Ram ^e  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer metastasis and angiogenesis; Heparanase; Non anticoagulant heparin; Pro coagulant activity; Tissue factor

Indexed keywords

HEPARAN SULFATE; HEPARANASE; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN;

ACETYLATION; ANGIOGENESIS; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CANCER; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CELL SURFACE; CELL SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE SILENCING; HEMOSTASIS; HUMAN; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SULFATION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

EID: 36048955098     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(07)70139-1     Document Type: Article

References (46)

1. Bernfield M., Gotte M., Park P., Reizes O., Fitzgerald M., Lincecum J., et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68 (1999) 729-777
2. Iozzo R. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67 (1998) 609-652
3. Sasisekharan R., Shriver Z., Venkataraman G., and Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2 (2002) 521-528
4. Vlodavsky I., Miao H., Medalion B., Danagher P., and Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15 (1996) 177-186
5. Parish C., Freeman C., and Hulett M. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471 (2001) M99-M108
6. Vlodavsky I., and Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108 (2001) 341-347
7. McKenzie E. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151 (2007) 1-14
8. Levy-Adam F., Miao H., Heinrikson R., Vlodavsky I., and Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308 (2003) 885-891
9. Nardella C., Lahm A., Pallaoro M., Brunetti M., Vannini A., and Steinkuhler C. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43 (2004) 1862-1873
10. Hulett M., Hornby J., Ohms S., Zuegg J., Freeman C., Gready J., et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39 (2000) 15659-15667
11. Abboud-Jarrous G., Rangini-Guetta Z., Aingorn H., Atzmon R., Elgavish S., Peretz T., et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 280 (2005) 13568-13575
12. Ilan N., Elkin M., and Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38 (2006) 2018-2039
13. Simizu S., Ishida K., and Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 95 (2004) 553-558
14. Elkin M., Ilan N., Ishai-Michaeli R., Friedmann Y., Papo O., Pecker I., et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 15 (2001) 1661-1663
15. Gingis-Velitski S., Zetser A., Flugelman M., Vlodavsky I., and Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279 (2004) 23536-23541
16. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., and Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66 (2006) 1455-1463
17. Shafat I., Zcharia E., Nisman B., Nadir Y., Nakhoul F., Vlodavsky I., et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341 (2006) 958-963
18. Miao H., Elkin M., Aingorn E., Ishai-Michaeli R., Stein C., and Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 83 (1999) 424-431
19. Parish C., Freeman C., Brown K., Francis D., and Cowden W. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59 (1999) 3433-3441
20. Vlodavsky I., Mohsen M., Lider O., Svahn C., Ekre H., Vigoda M., et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14 (1994) 290-302
21. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5 (1999) 793-802
22. Goldshmidt O., Zcharia E., Abramovitch R., Metzger S., Aingorn H., Friedmann Y., et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 99 (2002) 10031-10036
23. Edovitsky E., Elkin M., Zcharia E., Peretz T., and Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96 (2004) 1219-1230
24. Goldshmidt O., Zcharia E., Cohen M., Aingorn H., Cohen I., Nadav L., et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 17 (2003) 1015-1025
25. Nadir Y., Brenner B., Zetser A., Ilan N., Shafat I., Zcharia E., et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 4 (2006) 2443-2451
26. Vreys V., Delande N., Zhang Z., Coomans C., Roebroek A., Durr J., et al. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 280 (2005) 33141-33148
27. Lazo-Langner A., Goss G., Spaans J., and Rodger M. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5 (2007) 729-737
28. Lee A., Rickles F., Julian J., Gent M., Baker R., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
29. Sorensen H., Mellemkjaer L., Olsen J., and Baron J. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
30. Borsig L., Wong R., Feramisco J., Nadeau D., Varki N., and Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98 (2001) 3352-3357
31. Hostettler N., Naggi A., Torri G., Ishai-Michaeli R., Casu B., Vlodavsky I., et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J (2007) [Jun 8; Epub ahead of print.]
32. Bar-Ner M., Eldor A., Wasserman L., Matzner Y., Cohen I., Fuks Z., et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 70 (1987) 551-557
33. Naggi A., Casu B., Perez M., Torri G., Cassinelli G., Penco S., et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280 (2005) 12103-12113
34. Vlodavsky I., Ilan N., Naggi A., and Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharmacol Design 13 (2007) 2057-2073
35. Sanderson R., Yang Y., Suva L., and Kelly T. Heparan sulfate proteoglycans and heparanase partners in osteolytic tumor growth and metastasis. Matrix Biol 23 (2004) 341-352
36. Yang Y., Macleod V., Dai Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) [May 29; Epub ahead of print.]
37. Casu B., Petitou M., Provasoli M., and Sinäy P. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci 13 (1988) 221-225
38. Hricovini M., Guerrini M., Bisio A., Torri G., Naggi A., and Casu B. Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution. Semin Thromb Hemost 28 (2002) 325-334
39. Levy-Adam F., Abboud-Jarrous G., Guerrini M., Beccati D., Vlodavsky I., and Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 280 (2005) 20457-20466
40. Rao L., and Pendurthi U. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 25 (2005) 47-56
41. Rickles F., Patierno S., and Fernandez P. Tissue factor, thrombin, and cancer. Chest 124 (2003) 58S-68S
42. Vlodavsky I., Eldor A., Haimovitz-Friedman A., Matzner Y., Ishai-Michaeli R., Lider O., et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12 (1992) 112-127
43. Ohsawa M., Koyama T., Nara N., and Hirosawa S. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Thromb Res 112 (2003) 313-320
44. Zhang Y., Deng Y., Luther T., Muller M., Ziegler R., Waldherr R., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94 (1994) 1320-1327
45. Yahalom J., Fibach E., Bar-Tana R., Fuks Z., and Vlodavsky I. Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix. Leuk Res 12 (1988) 711-717
46. Nasser N., Sarig G., Brenner B., Nevo E., Goldshmidt O., Zcharia E., et al. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost 4 (2006) 560-565